Immune checkpoints may predict ALS severity, progression
Immune checkpoint proteins — proteins that help regulate immune response — were elevated on T-cells and in the blood of…
Articles by Margarida Maia, PhD
New trial to test effectiveness of COYA 302 to slow ALS progression
Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling…
In trial, Neuronata-R benefits ALS patients with slower progression
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally…
New analysis shows Radicava ORS slows ALS decline
A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation…
Repurposed vet drug helps ALS patients live longer: Study
A veterinary medication repurposed as a treatment for amyotrophic lateral sclerosis (ALS) helped patients live longer and slowed disease…
Plans in place for Phase 3 testing of ALS therapy NP001 next year
Neuvivo and the U.S. Food and Drug Administration (FDA) have agreed on a regulatory pathway toward the potential approval…
Loss of protein in ALS silences key nerve cell communication gene
In amyotrophic lateral sclerosis (ALS), the loss of any one of four RNA-binding proteins turns off a gene called…
AUT00201 boosts muscle strength, coordination in ALS mouse model
AUT00201, an experimental oral small molecule being developed by Autifony Therapeutics, reduced the loss of motor neurons — the…
Longitude Prize on ALS encourages use of AI to find new treatments
The Longitude Prize on ALS is offering a total of £7.5 million (more than $10 million) to encourage scientists…
Thousands in US use ALS treatment Radicava ORS, company says
Three years after its approval in the U.S., Radicava ORS (edaravone) has been prescribed by more than 1,300 healthcare…